Comparison between fixed-dose, intracoronary bolus-only versus standard weight-adjusted dose, intravenous bolus and infusion administration of abciximab in patients undergoing primary percutaneous coronary intervention

Abstract

We studied the safety and effectiveness of fixed-dose, intracoronary bolus-only abciximab in 195 patients who underwent primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. The patients were divided into 2 groups: Group A (n=120, 61.5%) received fixed-dose, intracoronary bolus-only, abciximab 10 mg; and Group B (n=75, 38.5%) received standard intravenous bolus (0.25 mg/kg) and maintenance abciximab infusion of 0.125 μg/kg/min for 12 h. There was no statistically significant difference in the baseline and post-procedure TIMI flow between Groups A and B. Final TIMI 3 flow was achieved in 90.0% and 89.3% of the patients in Groups A and B, respectively (p=0.14). Final TIMI myocardial perfusion grade 2/3 was achieved in 92.5% and 96.0% of the patients in Groups A and B, respectively (p=0.45). The six-month clinical outcomes were similar between Groups A and B (8.3% versus 5.3%, p=0.62).